Trial Profile
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 02 Feb 2024 Planned End Date changed from 20 Jan 2024 to 20 Jan 2025.
- 02 Feb 2023 Planned End Date changed from 20 Jan 2023 to 20 Jan 2024.
- 04 Feb 2022 Planned End Date changed from 28 Sep 2022 to 20 Jan 2023.